Overview
Hypophysitis refers to inflammatory conditions affecting the pituitary gland, leading to dysfunction that can manifest as hormonal imbalances and pituitary insufficiency. It encompasses various subtypes including lymphocytic hypophysitis, autoimmune forms, and secondary causes like immune checkpoint inhibitor (ICI) therapy 123.Diagnosis
Pituitary function tests: Essential for assessing hormonal deficiencies.
Imaging: Pituitary MRI is crucial for morphological assessment 2.
Laboratory tests: Tailored based on clinical suspicion, including electrolytes (e.g., hyponatraemia) 1.
Biopsy: Definitive but invasive; reserved for specialized settings 3.Management
Glucocorticoids: First-line treatment for symptomatic hypophysitis 23.
- High-dose glucocorticoids: 1 mg/kg prednisolone for two weeks, followed by tapering 1.
- Replacement dose: Hydrocortisone 20 mg total daily dose for maintenance 1.
Tapering schedule: Gradual reduction post-initial high-dose therapy 1.
Monitoring: Regular assessment of hormonal axes recovery and electrolyte balance 1.Special Populations
Immune checkpoint inhibitor-associated hypophysitis: Specific management with high-dose glucocorticoids may improve recovery rates 1.
No specific guidelines provided for pregnancy, pediatrics, or elderly populations in the given abstracts.Key Recommendations
Use high-dose glucocorticoids for initial treatment in ICI-associated hypophysitis to potentially enhance hormonal recovery (Evidence: Strong 1).
Initiate glucocorticoid replacement therapy with hydrocortisone for maintenance in cases where high-dose therapy is not indicated or insufficient (Evidence: Moderate 12).
Routine pituitary MRI and functional testing are essential for diagnosis and monitoring of hypophysitis (Evidence: Moderate 2).
Consider individualized tapering schedules for glucocorticoids based on clinical response (Evidence: Expert opinion 1).References
1 Theiler-Schwetz V, Trummer C, Schmitt L, Terbuch A, Obermayer-Pietsch B, Richtig E et al.. High-dose glucocorticoid treatment vs. glucocorticoid replacement in immune checkpoint inhibitor associated hypophysitis (CORTICI): an open, randomised controlled trial. Annals of medicine 2025. link
2 Iglesias P, Biagetti B, Guerrero-Pérez F, Vicente A, Cordido F, Díez JJ. Executive summary of the consensus document on hypophysitis of the Neuroendocrinology Area of Knowledge of the Spanish Society of Endocrinology and Nutrition. Endocrinologia, diabetes y nutricion 2023. link
3 Takagi H, Iwama S, Sugimura Y, Takahashi Y, Oki Y, Akamizu T et al.. Diagnosis and treatment of autoimmune and IgG4-related hypophysitis: clinical guidelines of the Japan Endocrine Society. Endocrine journal 2020. link